# EDGAR Filing Document

**Accession Number:** 0001207638
**File Stem:** 0001829126-26-005261
**Filing Date:** 2026-5
**Character Count:** 10968
**Document Hash:** 9908f66447fed1ed3162603e7ef57a02
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-005261.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001829126-26-005261

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zeo ScientifiX, Inc.
- **CENTRAL INDEX KEY:** 0001557376
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474180540
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87575
- **FILM NUMBER:** 26981828

**BUSINESS ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314
- **BUSINESS PHONE:** 888-963-7881

**MAIL ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Organicell Regenerative Medicine, Inc.
- **DATE OF NAME CHANGE:** 20180625

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biotech Products Services & Research, Inc.
- **DATE OF NAME CHANGE:** 20150917

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BESPOKE TRICYCLES INC
- **DATE OF NAME CHANGE:** 20120831
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BOTHWELL IAN T
- **CENTRAL INDEX KEY:** 0001207638

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 77 530 ENFIELD LANE
- **STREET 2:** BLDG D
- **CITY:** PALM DESERT
- **STATE:** CA
- **ZIP:** 92211

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Zeo Scientifix, Inc.**

*(Name of Issuer)*

**Shares of Common Stock $0.001 Par Value and Series C Preferred Stock $.001 Par Value**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Ian T. Bothwell**<br>3321 College Avenue<br>Suite 246<br>Davie FL 33314<br>888-963-7881

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/14/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**IAN T BOTHWELL** | Name of reporting person<br>**IAN T BOTHWELL** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**SC** | Source of funds (See Instructions)<br>**SC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1195094.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1195094.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1195094.00** | Aggregate amount beneficially owned by each reporting person<br>**1195094.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**14.7%** | Percent of class represented by amount in Row (11)<br>**14.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The number of shares Beneficially Owned by the Reporting Person consists of 1,195,094 shares of common stock (including 87,500 shares of restricted stock vesting on July 14, 2026, 187,500 shares issuable upon exercise of warrants and 180,000 shares issuable upon exercise of options held by the Reporting Person) representing 14.7% of the voting power based on 7,777,441 shares of common stock outstanding as of March 16, 2026, as reported by the Issuer in its January 31, 2026 Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on March 17, 2026 and giving effect to the exercise of the warrants and options held by the Reporting Person. In addition, the Reporting Person holds 50 shares of Series C Preferred Stock which provides the Reporting Person with an additional 25.5% of the total voting power. Accordingly, the Reporting Person's aggregate voting power is equal to 40.2%.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Shares of Common Stock $0.001 Par Value and Series C Preferred Stock $.001 Par Value

**(b) Name of Issuer:**
Zeo Scientifix, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
3321 College Avenue, Suite 246, Davie, FL, 33314

This Amendment No. 3 to the Statement on Schedule 13D ("Amendment No. 3") filed with the Securities and Exchange Commission (the "SEC") on August 16, 2018 (the "Schedule 13D"), on behalf of Ian Bothwell (the "Reporting Person"), with respect to the common stock of Zeo ScientifiX, Inc. (the "Issuer"), is being filed pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to amend and supplement certain information set forth below in the items indicated. All capitalized terms used in this Amendment No. 3 and not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D and or Amendments No. 1 and No. 2 filed with the SEC on August 20, 2021 and January 7, 2025, respectively. Except as amended and supplemented herein, the Schedule 13D, including the definitions of capitalized terms not otherwise defined herein, remains in full force and effect.

**Item 4. Purpose of Transaction**

The additional shares of the Issuer's common stock acquired by the Reporting Person as reported in Item 5(c) of and elsewhere in this Amendment No. 3, were issued to the Reporting Person as described in Item 3, above. The Reporting Person has no definite plan to acquire or dispose of additional shares of the Issuer's common stock in open market or private transactions, but may do so in the future, subject to compliance with the Exchange Act and the rules and regulations thereunder. In addition, while there is no definite plan to issue additional shares of the Issuer's common stock to the Reporting Person under one or more of the Issuer's equity incentive plans, the board of directors or a committee thereof may determine to issue awards of shares of common stock under such plans to the Reporting Person from time to time in the future.

Except as set forth in the preceding paragraph, the Reporting Person has no plans or proposals which relate to or would result in:

(a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer;

(b) Any additional extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries;

(c) A sale or transfer of a material amount of assets of the issuer or any of its subsidiaries;

(d) Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

(e) Any material change in the present capitalization or dividend policy of the issuer;

(f) Any other material change in the issuer's business or corporate structure including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940;

(g) Changes in the issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;

(h) Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

(i) A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(j) Any action similar to any of those enumerated above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the filing date of this Amendment No. 3, the Reporting Person beneficially owns 1,195,094 shares of the common stock of the Issuer (including 87,500 shares of restricted stock vesting on July 14, 2026, 187,500 shares issuable upon exercise of warrants and 180,000 shares issuable upon exercise of options held by the Reporting Person), representing 14.7% of the class after giving effect to the exercise of warrants and options held by the Reporting Person (the Reporting Person also holds 50 shares of Series C Preferred Stock which provides the Reporting Person with an additional 25.5% of the total voting power of the Issuer);

**(b)**
The Reporting Person has sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of all of the 1,195,094 shares; and

**(c)**
The Reporting Person has effected the following transactions in the class of securities reported on (the Issuer's common stock) since the most recent filing of Schedule 13D (ss.240.13d-101): Date Nature of the Transaction Number of Shares Price 05/08/2025 Grant of stock options under the Issuer's 2021 Equity Incentive Plan (the "Plan") 55,000 $0.00 01/14/2026 Grant of restricted shares under the Plan 175,000 $0.00

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

There are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** IAN T BOTHWELL

**Signature:** /s/ Ian T. Bothwell

**Name/Title:** Ian T. Bothwell

**Date:** 05/15/2026